Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1283694
Editorial: Plant-based drugs: the potential novel therapeutic intervention against cancer stemness and metastasis
- 1The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
- 2Laboratory of Synthetic Immunology, Cancer Immunotherapy Program, Division of Cancer Research, Rajiv Gandhi Center for Biotechnology, Thiruvananthapuram, Kerala, India
- 3Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi Campus, Kochi, Kerala, India
- 4Department of Ophthalmology, Keck School of Medicine, USC Roski Eye Institute, University of Southern California, Los Angeles, CA, United States
- 5Clinical Pharmacology and Bioanalysis, Princeton, NJ, United States
Editorial on the Research Topic
Plant-based drugs: the potential novel therapeutic intervention against cancer stemness and metastasis
Cancer is the second most common fatal disease leading to death worldwide. Metastatic growth in distant organs is the main reason for increased cancer mortality (Steinbichler et al., 2020). Cancer stem cells (CSCs) play a vital role in each step of the metastatic cascade, from cancer cell invasion into blood vessels, survival in the bloodstream, attachment and extravasation to colonization of the host organ and subsequent formation of macro and micro metastases (Gupta et al., 2021). CSCs are a small subpopulation of cells in tumors with self-renewal and differentiation capabilities that contribute to tumor growth, recurrence and metastatic spread. No successful therapies have been developed that target cancer stem cells to prevent metastasis. Currently available cancer treatment approaches including surgical resection, radiotherapy and chemotherapy are not sufficient to target CSCs (Yang et al., 2020). Therefore, we need to focus more on CSC as a major cause of cancer metastasis and compile the latest research to design future studies targeting CSC. Our Research Topic aims to explore current and future strategies for CSC targeted cancer therapies to prevent cancer metastasis in a way that is promising for patients. This editorial aims to provide a brief overview of the current state of research in this area and to highlight the promising aspects and challenges. This Research Topic comprises of five articles, including two original research articles, two reviews and one systemic review.
Cancer stem cells promote metastasis through multiple signaling pathways such as Wnt, Notch, Hh, NF-κB, JAK-STAT and TGFβ/SMAD which can enhance the stemness properties of cancer cells and lead to metastasis (Yang et al., 2020). It is challenging to target cancer stem cells as a population in a cancerous tumor. Therefore, developing therapies targeting cancer stem cells could open up new ways to treat metastatic cancer by disabling these signaling pathways. Plant-derived bioactive compounds gained considerable attention as potential new therapeutic interventions against cancer stem cells and metastases (Gupta et al., 2021). Metabolites derived from various plants have shown promising anticancer properties in preclinical studies. These metabolites can act on multiple signaling pathways involved in cancer stem cell formation, self-renewal, stem cell differentiation and apoptosis in cancer cells (Yang et al., 2020). By targeting CSCs, herbal medicines can potentially overcome treatment resistance and reduce the risk of tumor recurrence and metastasis. Several plant metabolites such as curcumin from turmeric, resveratrol from grapes, quercetin from fruits and vegetables and epigallocatechin gallate from green tea have been extensively studied for their anticancer effects on CSCs and metastases in various in vivo mouse models targeting cancer stem cells and their signaling pathways (Ramasamy et al., 2015; Wang et al., 2018; Namiki et al., 2020; Qin et al., 2020; Liao et al., 2023). However, the low bioavailability of plant metabolites as therapeutic agents is a significant limitation. Nevertheless, modifications by structural analogues and special formulations are a promising combination therapy in cancer treatment with chemotherapy and radiotherapy (Hegde et al., 2023). This combination helps to counteract metastasis and is thus an advance in pharmacological and therapeutic terms. Recent studies, including a clinical study of curcumin in patients with invasive breast cancer (NCT03980509) and clinical trials of resveratrol against gastric cancer, illustrate the therapeutic importance of phytometabolites (Honari et al., 2019; Howells et al., 2019; Ostwal et al., 2022). Most of these studies relate to a late recurrence stage with a probable accumulation of CSCs, which offers the opportunity to investigate the effects of plant metabolites on CSCs.
The exploration of plant derived drugs as potential therapeutic interventions against cancer stem cells and metastasis is an exciting area of research that complement existing cancer therapies and improve patient outcomes. Yuan et al. demonstrate the ability of plant metabolite triptolide to suppress glioblastoma tumor. Triptolide transcriptionally suppresses the expression of PROX1 in glioblastoma cells. This metabolite inhibits glioblastoma cell growth, apoptosis, proliferation, migration and invasion, thereby reducing the metastatic potential of glioblastoma. A few clinical studies have been carried out to evaluate their safety and efficacy focusing on phytomedicines targeting drug resistant CSCs and cancer cells. The review article by Zhang et al. illustrate on many of the active ingredients in traditional Chinese herbal medicine (TCM) which are effective in treating pancreatic cancer. The article focuses on the mode of action of bioactive plant metabolites from TCM against various signaling pathways such as Wnt and Notch, which regulate cancer stem cells in pancreatic cancer. Zhang et al. explain the inhibition of cancer stem cell signaling pathways involved in epithelial to mesenchymal transition, migration, metastasis and apoptosis of pancreatic cancer cells by the plant metabolites.
Targeted therapies for the heterogeneous population of cancer tumors and multidrug resistance associated with cancer stem cells are still not effectively established. The review article by Koklesova et al. describes how nanoparticles specifically designed to target cancer stem cells in tumor, serve as carriers for targeted delivery of plant-based drugs. Several Nano-drugs developed to target and treat the different types of cancer and their subsequent CSCs are discussed. Plant metabolite-based nanoparticles are modified to specifically target cancer stem cells, which helps in reducing the risk of tumor recurrence and the manifestation of metastases. Zhao et al. describe the anti-metastatic effect of thymoquinone in pancreatic cancer and its sensitivity to gemcitabine by regulating collagen. In pancreatic cancer cells, thymoquinone promotes apoptosis, inhibits tumor cell migration, invasion and metastasis, and sensitizes pancreatic cancer cells to gemcitabine. Furthermore, the study shows that thymoquinone stimulates cellular matrix production via TGFβ/Smad pathways.
Studies show that flavonoids have an anticancer effect against various types of cancer. Flavonoids can induce apoptosis and autophagic cell death of breast cancer cells, inhibit cancer proliferation and overcome drug resistance of cancer tumors (Mazurakova et al.). In the systemic review article, Mazurakova et al. detail the effect of flavonoids on breast cancer stem cells to combat therapy resistance and cancer proliferation. The accumulation of breast cancer stem cells (BCSCs) after chemotherapy, prevents further effective treatment of breast cancer patients. Therefore, it is also postulated that eradication of BCSCs in combination with standard cytotoxic drugs and flavonoids specifically targeting CSCs in breast cancer tumor is essential for successful treatment.
This Research Topic provides new data and detailed reviews on plant-derived compounds that target cancer stem cells and inhibit metastasis through various mechanisms of action by modulating self-renewal pathways, suppressing EMT, affecting the tumor microenvironment and disrupting signaling pathways essential for cancer cell migration, invasion and survival. Thus, plant metabolites are promising for developing innovative therapeutic strategies against cancer stem cells and metastasis. Prospective research is inevitable to successfully translate research findings into clinical trials by addressing challenges such as safety, bioavailability, formulation and standardization of herbal medicines. These findings and reviews demonstrate how phytomedicines targeting cancer stem cells significantly reduce metastasis and subsequent mortality. These prospective and innovative findings, if clinically established, are promising and can pave the way to new vistas for cancer therapy.
VL: Writing–original draft, Writing–review and editing, Formal Analysis, Supervision. SM: Writing–review and editing. LN: Writing–review and editing. GG: Writing–review and editing. HT: Writing–review and editing.
We would like to sincerely thank all the authors for their scientific contributions to this Research Topic, as well as the reviewers for their time, effort, comments, and constructive criticism in refining the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Gupta, P. K., Saraff, M., Gahtori, R., Negi, N., Tripathi, S. K., Kumar, J., et al. (2021). Phytomedicines targeting cancer stem cells: Therapeutic opportunities and prospects for pharmaceutical development. Pharmaceuticals 14 (7), 676. doi:10.3390/ph14070676
Hegde, M., Sosmitha, G., Bandari, B., Chetty, R. V., and Ajaikumar, B. K. (2023). Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far? ACS omega 8 (12), 10713–10746. doi:10.1021/acsomega.2c07326
Honari, M., Shafabakhsh, R., Reiter, R. J., Mirzaei, H., and Asemi, Z. (2019). Resveratrol is a promising agent for colorectal cancer prevention and treatment: focus on molecular mechanisms. Cancer Cell. Int. 19 (1), 180–188. doi:10.1186/s12935-019-0906-y
Howells, L. M., Iwuji, C. O., Irving, G. R., Barber, S., Walter, H., Sidat, Z., et al. (2019). Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. J. Nutr. 149 (7), 1133–1139. doi:10.1093/jn/nxz029
Liao, W., Zhang, L., Chen, X., Xiang, J., Zheng, Q., Chen, N., et al. (2023). Targeting cancer stem cells and signalling pathways through phytochemicals: A promising approach against colorectal cancer. Phytomedicine 108, 154524. doi:10.1016/j.phymed.2022.154524
Namiki, K., Wongsirisin, P., Yokoyama, S., Sato, M., Rawangkan, A., Sakai, R., et al. (2020). (-)-Epigallocatechin gallate inhibits stemness and tumourigenicity stimulated by AXL receptor tyrosine kinase in human lung cancer cells. Sci. Rep. 10 (1), 2444. doi:10.1038/s41598-020-59281-z
Ostwal, V., Ramaswamy, A., Bhargava, P., Srinivas, S., Mandavkar, S., Chaugule, D., et al. (2022). A pro-oxidant combination of resveratrol and copper reduces chemotherapy-related non-haematological toxicities in advanced gastric cancer: results of a prospective open label phase II single-arm study (RESCU III study). Med. Oncol. 40 (1), 17. doi:10.1007/s12032-022-01862-1
Qin, T., Cheng, L., Xiao, Y., Qian, W., Li, J., Wu, Z., et al. (2020). NAF-1 inhibition by resveratrol suppresses cancer stem cell-like properties and the invasion of pancreatic cancer. Front. Oncol. 10, 1038. doi:10.3389/fonc.2020.01038
Ramasamy, T. S., Ayob, A. Z., Myint, H. H. L., Thiagarajah, S., and Amini, F. (2015). Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy. Cancer Cell Int. 15 (1), 96–15. doi:10.1186/s12935-015-0241-x
Steinbichler, T. B., Savic, D., Dudás, J., Kvitsaridze, I., Skvortsov, S., Riechelmann, H., et al. (2020). Cancer stem cells and their unique role in metastatic spread. Semin. Cancer Biol. 60, 148–156. doi:10.1016/j.semcancer.2019.09.007
Wang, R., Yang, L., Li, S., Ye, D., Yang, L., Liu, Q., et al. (2018). Quercetin inhibits breast cancer stem cells via downregulation of aldehyde dehydrogenase 1A1 (ALDH1A1), chemokine receptor type 4 (CXCR4), mucin 1 (MUC1), and epithelial cell adhesion molecule (EpCAM). Med. Sci. Monit. 24, 412–420. doi:10.12659/msm.908022
Keywords: phytomedicine, cancer stem cells, metastasis, drug resistant, therapeutic, tumor recurrence
Citation: Liju VB, Martin S, Nath LR, Gopinadhan Nair GK and Thayele Purayil H (2023) Editorial: Plant-based drugs: the potential novel therapeutic intervention against cancer stemness and metastasis. Front. Pharmacol. 14:1283694. doi: 10.3389/fphar.2023.1283694
Received: 26 August 2023; Accepted: 29 September 2023;
Published: 06 October 2023.
Edited and reviewed by:Michael Heinrich, University College London, United Kingdom
Copyright © 2023 Liju, Martin, Nath, Gopinadhan Nair and Thayele Purayil. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.